ArticleMetabolic brain disease2024
Vetiveria zizanioides modulates experimental epilepsy-induced seizures, oxidative stress, and apoptosis in the brain of rats.
Article in Metabolic brain disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we investigated the protective actions of Vetiveria zizanioides oil (VET) against oxidative stress and apoptosis in a rat model of pentylenetetrazol (PTZ)-induced epilepsy model. Rats were divided into four groups: control (1 ml/kg saline, by gavage, 7 days + 1 ml/kg saline, i.p, single dose, 8th day), PTZ (1 ml/kg saline, by gavage, 7 days + 60 mg/kg, i.p, single dose, 8th day), PTZ + VET-200 (200 mg/kg VET, by gavage, 7 days + 60 mg/kg PTZ, i.p, single dose, 8th day), and PTZ + VET-400 (400 mg/kg VET, by gavage, 7 days + 60 mg/kg PTZ i.p, single dose, 8th day). Behavioral evaluation (Racine scale was used to classify the severity of seizures according to stages) and EEG recordings were taken. At the end of the experiment, the animals were sacrificed, and blood, hippocampus, and cerebral cortex tissues were removed for biochemical and histopathological examinations. PTZ injection increased the duration of the first epileptic spike and the total number of seizures and caused oxidative stress by increasing the total oxidant status (TOS). The treatment of PTZ induced neurodegenerative changes in the tissues such as increases of apoptosis, Bcl-2, Cyclin B1, and GABA expressions, but decreased Beta-tubulin. However, all the adverse changes of PTZ were modulated by the treatment of VET-200 and VET-400. In conclusion, these results showed that VET could ameliorate epileptic seiures, oxidative stress, and neuronal apoptosis in PTZ-induced seizures.
Indexed as
Identifiers
39576294What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.